Pegvisomant and cabergoline combination therapy in acromegaly

Area of Science:

• Endocrinology
• Pharmacology
• Oncology

Background:

• Acromegaly, a condition caused by excess growth hormone, often requires multifaceted treatment approaches.
• Pegvisomant monotherapy is used for acromegaly, but some patients exhibit partial resistance.
• Cabergoline is a dopamine agonist that may offer synergistic effects when combined with pegvisomant.

Purpose of the Study:

• To evaluate the safety and efficacy of combining cabergoline with pegvisomant in acromegaly patients.
• To identify clinical and biochemical factors influencing the response to this combination therapy.

Main Methods:

• An observational, retrospective, cross-sectional study was conducted.
• Fourteen acromegalic patients on pegvisomant monotherapy with persistent elevated IGF-I were included.
• Cabergoline was added, and the combination's efficacy and safety were assessed over a mean follow-up of 18.3 months.

Main Results:

• Insulin-like growth factor-I (IGF-I) normalized in 28% of patients and decreased in an additional 5 patients.
• Mean %IGF-I decreased significantly from 158% to 124% (p=0.001).
• Better response was associated with lower baseline IGF-I, female gender, lower body weight, and higher prolactin levels. No severe adverse events were reported.

Conclusions:

• Combination therapy with pegvisomant and cabergoline can improve IGF-I control in select acromegaly patients.
• Baseline IGF-I, gender, body weight, and prolactin levels are key determinants of treatment efficacy.
• This combination represents a potential therapeutic option for managing difficult-to-treat acromegaly.